Matwings Technology and Revvity Reach Strategic Cooperation to Jointly Build an AI for Science Innovation Ecosystem

On October 29, Shanghai Matwings Technology Co., Ltd. and Revvity formally signed a strategic cooperation agreement. The two parties will carry out in-depth innovation cooperation around AI for Science, with "algorithm + hardware intelligent manufacturing" two-way empowerment as the core, to accelerate scientific discovery and the translation of results in the life sciences field.

Hong Liang, founder and chief scientist of Matwings Technology, and Liu Jiang, vice president of Revvity and general manager of Greater China, signed the agreement on behalf of the two parties. Li Mingchen, chief technical scientist of the Matwings Technology AI Lab, Luo Kuan, director of government affairs of Matwings Technology and head of the dark laboratory, Zheng Yin, marketing director of Revvity Greater China, and Li Yuhu, head of the Revvity life sciences market development business team, jointly attended and witnessed the signing ceremony.

Scene of the strategic cooperation signing ceremony between Matwings Technology and Revvity

At present, artificial intelligence is reshaping life science research. However, the realization of AI value is highly dependent on efficient experimental validation systems, automated experimental platforms and digital scientific research infrastructure. How to break through the barriers between computational prediction and experimental validation and build a continuously iterating R&D closed loop is the key to the large-scale application of AI for Science.

Matwings Technology empowers protein R&D with AI technology and provides full-chain AI solutions for fields such as biomedicine and biomanufacturing. Relying on the MatwingsVenus® (Xiaowu®) dry-wet closed-loop protein R&D platform, it connects computational design and automated experimental validation to accelerate the translation of innovative results into industrial applications. After more than 30 years of continuous accumulation, Revvity has deployed more than 600 automation systems worldwide[1]. Its automation capabilities have expanded from high-throughput screening to frontier research fields such as genomics, organoids and synthetic biology, and it has mature capabilities to support the upgrade of traditional linear R&D models to efficient closed-loop systems.

Based on Matwings Technology's innovation capabilities in AI large models, protein design and biological computing, and in conjunction with Revvity's deep accumulation in laboratory automation and life science solutions and the localized resources of its Taicang R&D and production base, the two parties will focus on core scenarios such as drug R&D, protein engineering and biomanufacturing, explore the future-oriented Lab-in-the-Loop R&D model, and create a full-chain integrated solution of "AI algorithms + high-end scientific research hardware + experimental services."

Hong Liang, founder and chief scientist of Matwings Technology, said: "AI is accelerating the innovation of life science R&D models. This cooperation will further promote the combination of artificial intelligence technology and experimental science scenarios and drive continuous optimization of scientific research processes. Running through the entire value chain from target discovery to industrial implementation, Revvity is a solid enabler and long-term partner for global innovative drug R&D. We look forward to leveraging our respective advantages with Revvity to jointly explore new paths for AI-driven scientific discovery and provide more possibilities for innovative development in the biomedicine and life sciences fields."

Liu Jiang, vice president of Revvity and general manager of Greater China, said: "The value of AI lies not only in the model itself, but also in the implementation efficiency of experimental validation and continuous iteration. Revvity has long been deeply engaged in the integrated innovation of instruments, reagents and automated workflows, while Matwings Technology has outstanding advantages in AI large models, protein design and biological computing. The two parties are joining hands to promote the deep integration of experimental science and artificial intelligence, jointly create a new paradigm of AI for Science, accelerate the implementation of innovative results, and inject momentum into the life sciences industry."

About Matwings Technology

Matwings Technology is an artificial intelligence company focused on the life sciences field, committed to connecting computational design, wet experimental validation, process scale-up and commercial application. The company now provides full-chain AI solutions covering R&D, pilot testing, production and quality control for fields such as biomedicine and biomanufacturing. Its self-developed dry-wet closed-loop protein R&D platform MatwingsVenus® (Xiaowu®) is also helping individuals and biotech companies improve R&D efficiency and accelerate innovative results from design to large-scale production.

English text is being prepared.

About Revvity

At Revvity, we regard "impossible" as inspiration and "cannot be done" as motivation. Revvity provides health science solutions, cutting-edge technologies and professional services, covering the end-to-end full process of scientific exploration, development, diagnosis and treatment. Relying on years of deep cultivation in fields such as translational multi-omics technologies, biomarker identification, imaging, disease prediction, screening, testing and diagnosis, and informatics, Revvity is using the power of technology to push the boundaries of human potential.

In 2025, Revvity's revenue was approximately US$2.9 billion, with approximately 11,000 employees worldwide, providing diversified services to customers such as pharmaceutical and biotechnology companies, diagnostic laboratories, scientific research institutions and government agencies. The company is a member of the S&P 500 Index, with customers in more than 160 countries and regions around the world.